PSA Decline After 4 Weeks of Abiraterone Suggests Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer
Since we have many new treatments for men with castrate resistant metastatic prostate cancer (mCRPC) (advanced prostate cancer) we need to develop earlier indicators of when a treatment might or might not be successful. A decline in prostate-specific antigen (PSA) is widely used to monitor treatment response, but it has not been validated as an endpoint for the very important goal, overall survival (OS). Abiraterone Acetate (Zytiga)(AA) is one of these newer treatments that we need to explore and understand when to switch or continue on with the drug . Solid metrics will help guide good clinical decision making. To [...]
Global Prostate Cancer Alliance investigates why Black men in the UK die at twice the rate as White men.
The Global Prostate Cancer Alliance requests your participation in a United Kingdom focused project regarding Prostate Cancer killing Black men at twice the rate as it does White descent. We want to understand how Black men in the UK manage their disease while facing this massive disparity. First are telephone interviews with Black men diagnosed with prostate cancer regarding their treatment experiences and quality of life. The interviews, which will be conducted anonymously, then reviewed and distributed in booklet and web based pdf. The USA interviews (which you can see at http://twiceasmany.org ) are almost complete and, today, we begin the UK arm. Please invite [...]
One of the frustrations faced by men in the UK has been the Guideline that restrictes the use of chemotherapy (docetaxel) to only men who have already failed hormone therapy (ADT). This Guideline directly contradicts the current, cutting edge evidence that, in certain circumstances, earlier chemotherapy increases survival. The good news is that the NHS has revisited this Guideline and, in their wisdom, agreed to modify it so that men, with advanced prostate cancer, can now be prescribed chemotherapy immediately. Now, men in the UK are able to access chemotherapy even while they remain sensitive to ADT. Given that prostate [...]
There has been a lot of conversation about the role of and the use of multi-parametric MRIs in the initial diagnostic stages of prostate cancer, but little is known about its potential clinical application in the use of early salvage radiotherapy after failed radical prostatectomy. In a study to exam the potential of multi-parametric MRIs in men experiencing surgical failure as defined by a rising PSA post surgery, researchers reviewed the records and MRI studies of 70 men with rising PSA scores post surgery. They evaluated the incidence and location of recurrence based on pelvic multi-parametric MRI findings and to [...]